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Chapter 9 Appendices - AD Causes Queries 
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(streptozotocin OR scopolamine OR colchicine OR LPS-induc* OR polymorphism* OR Abeta-
induc* OR "beta-amyloid-induc*" OR "amyloid-beta-induc*" OR "beta-amyloid peptide-
induc*" OR "Abeta25-35-induc*" OR "Abeta25-35 peptide-induc*" OR Abeta40-induc* OR 
nontoxic OR non-toxic)  
AND 
Remainder of Query Intersected with Core Literature 
II. TEXT FIELD TERMS 
IIA. NON-LIFESTYLE-SPECIFIC COMPONENT - TOPIC 
 ("2,4,6- triiodobenzoic acid" OR "3-deazaneplanocin A" OR "5AZA" OR "5-aza-deoxycytidine" 
OR "5-fluorouracil" OR "9-alpha fluorocortisol" OR "9-alpha fluoroprednisolone" OR "9-
hydroxy-2-methylellipticinium" OR "acarbose" OR "ACE inhibitor*" OR "acetaminophen" OR 
"acetazolamide" OR "acetylsalicylic acid" OR "acyclovir" OR "adalimumab" OR "adefovir" OR 
"adriamycin" OR "alclofenac" OR "aliskiren" OR "alizapride" OR "allopurinol" OR "all-trans-
retinoic acid" OR "alpha-mercaptopropionylglycine" OR "amikacin" OR "Aminoglycoside*" OR 
"Amiodarone" OR "amitriptyline" OR "amlodipine" OR "amoxicillin" OR "amphetamine*" OR 
"amphotericin b" OR "ampicillin" OR "ampiroxicam" OR "anabolic steroid*" OR 
"Anaesthetic*" OR "Analgesic*" OR "anasthesia" OR "androgen deprivation therapy" OR 
"anesthetic*" OR "anthracycline" OR "antiadrenergic agent*" OR "anti-adrenergic agent*" OR 
"antiadrenergic drug*" OR "anti-adrenergic drug*" OR "antiallergic agent*" OR "Anti-Allergic 
agent*" OR "antiallergic drug*" OR "Anti-Allergic drug*" OR "antiandrogen* agent*" OR 
"anti-androgen* agent*" OR "antiandrogen* drug*" OR "anti-androgen* drug*" OR "antianginal 
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agent*" OR "anti-anginal agent*" OR "antianginal drug*" OR "anti-anginal drug*" OR 
"antiangiogenesis agent*" OR "anti-angiogenesis agent*" OR "antiangiogenesis drug*" OR 
"anti-angiogenesis drug*" OR "antiarrhythmic agent*" OR "antiarrhythmic drug*" OR "anti-
arrythmatic agent*" OR "anti-arrythmatic drug*" OR "antiasthmatic agent*" OR "anti-asthmatic 
agent*" OR "antiasthmatic drug*" OR "anti-asthmatic drug*" OR "antibacterial agent*" OR 
"Anti-bacterial agent*" OR "antibacterial drug*" OR "Anti-bacterial drug*" OR "antibiotic*" OR 
"antibone-loss agent*" OR "Anti-Bone-Loss agent*" OR "antibone-loss drug*" OR "Anti-Bone-
Loss drug*" OR "anticholinergic agent*" OR "anti-cholinergic agent*" OR "anti-cholinergic 
drug*" OR "anticholinergic* drug*" OR "anticoagulant*" OR "Anti-coagulant*" OR 
"anticonvulsant*" OR "anti-convulsant*" OR "antidepressant*" OR "anti-depressant*" OR 
"Antidiabetic agent*" OR "anti-diabetic agent*" OR "Antidiabetic drug*" OR "anti-diabetic 
drug*" OR "antidiarrheal agent*" OR "anti-diarrheal agent*" OR "antidiarrheal drug*" OR "anti-
diarrheal drug*" OR "anti-emetic" OR "antiemetic*" OR "antifungal agent*" OR "anti-fungal 
agent*" OR "antifungal drug*" OR "anti-fungal drug*" OR "antigonadotropic agent*" OR "anti-
gonadotropic agent*" OR "antigonadotropic drug*" OR "anti-gonadotropic drug*" OR "antigout 
agent*" OR "anti-gout agent*" OR "antigout drug*" OR "anti-gout drug*" OR "antihistamine 
agent*" OR "anti-histamine agent*" OR "antihistamine drug*" OR "anti-histamine drug*" OR 
"Antihypertensive agent*" OR "anti-hypertensive agent*" OR "Antihypertensive drug*" OR 
"anti-hypertensive drug*" OR "antiinfective agent*" OR "Anti-Infective agent*" OR 
"antiinfective drug*" OR "Anti-Infective drug*" OR "anti-infective*" OR "antiinflammatory 
agent*" OR "Anti-Inflammatory agent*" OR "antiinflammatory drug*" OR "Anti-Inflammatory 
drug*" OR "antimalarial agent*" OR "anti-malarial agent*" OR "antimalarial drug*" OR "anti-
malarial drug*" OR "antimetabolite agent*" OR "anti-metabolite agent*" OR "antimetabolite 
drug*" OR "anti-metabolite drug*" OR "antimigraine agent*" OR "anti-migraine agent*" OR 
"antimigraine drug*" OR "anti-migraine drug*" OR "Antineoplastic Agent*" OR "anti-
neoplastic agent*" OR "Antineoplastic drug*" OR "anti-neoplastic drug*" OR "antiparkinson 
agent*" OR "anti-parkinson agent*" OR "antiparkinson drug*" OR "anti-parkinson drug*" OR 
"antiplatelet agent*" OR "anti-platelet agent*" OR "antiplatelet drug*" OR "anti-platelet drug*" 
OR "antipseudomonal agent*" OR "anti-pseudomonal agent*" OR "antipseudomonal drug*" OR 
"anti-pseudomonal drug*" OR "antipsoriatic agent*" OR "anti-psoriatic agent*" OR 
"antipsoriatic drug*" OR "anti-psoriatic drug*" OR "Antipsychotic Agent*" OR "Anti-psychotic 
agent*" OR "Antipsychotic drug*" OR "Anti-psychotic drug*" OR "Antiretroviral Agent*" OR 
"Anti-retroviral Agent*" OR "Antiretroviral drug*" OR "Antiretroviral drug*" OR "antiretroviral 
therapy" OR "Antirheumatic Agent*" OR "anti-rheumatic agent*" OR "Antirheumatic drug*" 
OR "anti-rheumatic drug*" OR "antiseptic agent*" OR "anti-septic agent*" OR "antiseptic 
drug*" OR "anti-septic drug*" OR "antispasmodic agent*" OR "anti-spasmodic agent*" OR 
"antispasmodic drug*" OR "anti-spasmodic drug*" OR "anti-thymocyte serum" OR "Antithyroid 
Agent*" OR "Anti-thyroid Agent*" OR "Antithyroid drug*" OR "Anti-thyroid drug*" OR 
"antitoxin*" OR "anti-toxin*" OR "antituberculosis agent*" OR "anti-tuberculosis agent*" OR 
"antituberculosis drug*" OR "anti-tuberculosis drug*" OR "antitussive agent*" OR "anti-tussive 
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agent*" OR "antitussive drug*" OR "anti-tussive drug*" OR "antivenin*" OR "antivertigo 
agent*" OR "anti-vertigo agent*" OR "antivertigo drug*" OR "anti-vertigo drug*" OR "Antiviral 
agent*" OR "Anti-viral agent*" OR "Antiviral drug*" OR "Anti-viral drug*" OR "aprotinin" OR 
"aspirin" OR "AT1 receptor antagonists" OR "atazanavir" OR "atorvastatin" OR "axitinib" OR 
"azacitadine" OR "azathioprine" OR "azithromycin" OR "Azole*" OR "Barbiturate*" OR 
"bardoxolone methyl" OR "benfluorex" OR "benoxaprofen" OR "beta-lactam" OR 
"bevacizumab" OR "bezafibrate" OR "bisacodyl" OR "Bisphosphonate*" OR "Bleomycin" OR 
"bortezomib" OR "bucillamine" OR "bupivacaine" OR "buspirone" OR "caffeine" OR 
"calcineurin inhibitor*" OR "calcitriol" OR "Calcium Channel Blocker" OR "Calcium channel 
blocker*" OR "capecitabine" OR "captopril" OR "carbamazepine" OR "carbenoxolone" OR 
"carbimazole" OR "carboplatin" OR "Cardiovascular Agent*" OR "carmustine" OR "C-
arylsuccinimides" OR "cediranib" OR "cefdinir" OR "cefoxitin" OR "ceftriaxone" OR 
"cefuroxime" OR "celecoxib" OR "Central Nervous System Agent*" OR "cephaloridine" OR 
"cephalosporins" OR "Cephems" OR "cetuximab" OR "chlorambucil" OR "Chloramphenicol" 
OR "chlormezanone" OR "chloroquine" OR "Chlorpromazine" OR "chlorprothixene" OR 
"chlorthalidone" OR "cidofovir" OR "cimetidine" OR "ciprofibrate" OR "ciprofloxacin" OR 
"cisplatin" OR "clarithromycin" OR "clometacin" OR "clomipramine" OR "clopentixol" OR 
"clopidogrel" OR "cloxacillin" OR "clozapine" OR "colchicine" OR "colistin" OR "contrast 
medium" OR "coronary artery bypass" OR "corosolic acid" OR "Corticosteroid*" OR 
"cyclophosphamide" OR "cycloserine" OR "cyclosporine" OR "cytarabine" OR "cytosine 
arabinoside" OR "dasatinib" OR "daunomycin" OR "daunorubicin" OR "decitabine" OR 
"deferasirox" OR "deferoxamine" OR "demeclocycline" OR "deoxycorticosterone acetate" OR 
"desipramine" OR "dexamethasone" OR "dexfenfluramine" OR "dexmethylphenidate" OR 
"dextran" OR "diaziquone" OR "diclofenac" OR "didecyldimethylammonium chloride" OR 
"diethyacetylurea" OR "diflunisal" OR "Digitalis" OR "diltiazem" OR "diphenylhydantoin" OR 
"diphosphonates" OR "dipivalyl adrenaline hydrochloride" OR "dipyrone" OR "disopyramide" 
OR "Diuretic*" OR "doxepin" OR "doxorubicin" OR "doxycycline" OR "d-penicillamine" OR 
"dRK6" OR "efavirenz" OR "enoxaparin" OR "epoetin" OR "erythromycin" OR "erythropoietin" 
OR "esomeprazole" OR "etanercept" OR "ethambutol" OR "ethosuximide" OR "famotidine" OR 
"fenbufen" OR "fenclofenac" OR "fenfluramine" OR "fenofibrate" OR "fenoldopam" OR 
"fenoprofen" OR "Fibrate therapy" OR "flubiprofen" OR "flucloxacillin" OR "fluindione" OR 
"Fluoroquinolones" OR "flupenthixol" OR "fluphenazine" OR "flurbiprofen" OR 
"flurithromycin" OR "fondaparinux sodium" OR "foscarnet" OR "furantoin" OR "furosemide" 
OR "fusidic acid" OR "FYX-051" OR "gabapentin" OR "gadodiamide" OR "Gadolinium" OR 
"gadopentetate dimeglumine" OR "Gastrointestinal Agent*" OR "gatifloxacin" OR "GBCA" OR 
"GCCA" OR "gefitinib" OR "gemcitabine" OR "gemfibrozil" OR "gentamicin" OR 
"germicide*" OR "Glucocorticoid*" OR "glycyrrhizinic acid" OR "Haloperidol" OR 
"Halothane" OR "Hematologic Agent*" OR "heparin" OR "hetastarch" OR "high insulin" OR 
"hydralazine" OR "hydrochlorothiazide" OR "hydroxychloroquine" OR "hydroxyethylstarch" 
OR "hydroxymethylglutaryl-CoA reductase inhibitor*" OR "hylan G-F 20" OR "Hypnotic 
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Agent*" OR "iatrogenic" OR "ibuprofen" OR "ifosfamide" OR "IGF-1" OR "iloprost" OR 
"imatinib" OR "imipramine" OR "imiquimod" OR "Immunosuppressive Agent*" OR "indinavir" 
OR "indomethacin" OR "infliximab" OR "Interferon*" OR "intravenous immunoglobulin*" OR 
"Iodine" OR "iodixanol" OR "iohexol" OR "ionizing radiation" OR "iopamidol" OR "ioxilan" 
OR "iron sucrose" OR "iron-induced" OR "iron-overload" OR "isocarboxazid" OR "isoniazid" 
OR "isoprenaline" OR "ketamine" OR "Ketoconazole" OR "ketoprofen" OR "ketorolac" OR 
"lansoprazole" OR "lapatinib" OR "leflunomide" OR "levetiracetam" OR "levofloxacin" OR 
"Lipid Regulating Agent*" OR "lithium" OR "lopinavir" OR "loratadine" OR "loxapine" OR 
"mannitol" OR "maprotiline" OR "mefanamic acid" OR "meropenem" OR "mesalamine" OR 
"mesalazine" OR "mesoridazine" OR "metamizole" OR "metformin" OR "methicillin" OR 
"methimazole" OR "methocarbamol" OR "methotrexate" OR "methotrimeprazine" OR 
"methoxyflurance" OR "methyldopa" OR "methylphenidate" OR "methysergide" OR 
"metolazone" OR "metoprolol" OR "Metronidazole" OR "midecamycin acetate" OR 
"Mineralcorticoid*" OR "minocycline" OR "mirtazapine" OR "mitomycin" OR "Mood 
Stabilizer*" OR "morphine" OR "Movement Stabilizer*" OR "moxifloxacin" OR "Muscle 
Relaxant*" OR "Mustard gas" OR "muzolimine" OR "nafcillin" OR "naphazoline hydrochloride" 
OR "naproxen" OR "N-arylsuccinimides" OR "Nasal decongestant*" OR "nelfinavir" OR 
"neomycin" OR "Niacin" OR "nifedipine" OR "niflumic acid" OR "nimesulide" OR 
"nitrendipine" OR "nitrofurantoin" OR "nitrogen mustard" OR "Nitroglycerin" OR "nitrosureas" 
OR "nomifensine" OR "Nonsteroidal anti-inflammatory drug*" OR "norepinephrine" OR 
"norfloxacin" OR "nortriptyline" OR "NSAID*" OR "NVP-BKM120" OR "ofloxasin" OR 
"olanzapine" OR "olmetin" OR "olsalazine" OR "omeprazole" OR "orlistat" OR "oxaliplatin" 
OR "oxymetazoline hydrochloride" OR "oxytetracycline" OR "ozurdex" OR "paliperidone" OR 
"pamidronate" OR "panitumumab" OR "pantoprazole" OR "papaverine" OR "paracetamol" OR 
"paroxetine" OR "pazopanib" OR "pefloxacin" OR "Penams" OR "penicillamine" OR 
"penicillin" OR "pentamidine" OR "pentazocine" OR "pericyazine" OR "perphenazine" OR 
"phenacetin" OR "phenindione" OR "phenobarbital" OR "phenylbutazone" OR "phenylephrine" 
OR "phenylpropanolamine" OR "phenytoin" OR "phosphatidylinositol-3-kinase inhibitor*" OR 
"physostigmine" OR "pimozide" OR "piperacillin" OR "piroxicam" OR "pirprofen" OR "platalet 
aggregation inhibitor*" OR "polymyxin B" OR "pranlukast" OR "prednisolone" OR 
"Primaquine" OR "probenecid" OR "procainamide" OR "prochlorperazine" OR "propoxyphene" 
OR "propylthiouracil" OR "protamine" OR "Proton pump inhibitor*" OR "prulifloxacin" OR 
"pseudoephedrine hydrochloride" OR "ptu-induced" OR "puromycin" OR "quetiapine" OR 
"quinacrine" OR "quinidine" OR "quinine" OR "quinolone" OR "rabeprazole" OR 
"radiofrequency-induced cosmetic volume reduction" OR "ranitidine" OR "rapamycin" OR 
"rhuepo-induced" OR "rifampicin" OR "rifampin" OR "risperidone" OR "Ritalin" OR "ritodrine 
hydrochloride" OR "ritonavir" OR "rofecoxib" OR "rosuvastatin" OR "scopolamine" OR 
"selegiline" OR "sibutramine" OR "simvastatin" OR "sodium barbital" OR "sodium valproate" 
OR "sorafenib" OR "spirapril" OR "spironolactone" OR "Statin*" OR "Steroid*" OR 
"Stimulant*" OR "streptomycin" OR "streptozocin" OR "streptozotocin" OR "Succinimide 
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derivative*" OR "sulfadiazine" OR "sulfamethoxazole" OR "sulfasalazine" OR "Sulfonamide*" 
OR "sulfonylureas" OR "sulfur mustard" OR "sulindac" OR "sulphinpyrazone" OR "sulpiride" 
OR "sunitinib" OR "superdrol" OR "tacrolimus" OR "Tamoxifen" OR "tazobactam" OR 
"telazol" OR "telithromycin" OR "tenofovir" OR "testosterone" OR "tetrabenazine" OR 
"Tetracycline*" OR "tetrahydrozoline hydrochloride" OR "tetrandrine" OR "thiazides" OR 
"thiopropazate" OR "thioproperazine" OR "Thioridazine" OR "thiothixene" OR "thrombolytic 
therapy" OR "ticlopidine" OR "tiletamine" OR "tiopronin" OR "tobramicin" OR "triamterene" 
OR "trichostatin A" OR "Tricyclics" OR "trimethadione" OR "trimethoprim" OR "trimipramine" 
OR "tripelennamine" OR "valdecoxib" OR "Valproic Acid" OR "valpromide" OR "vancomycin" 
OR "venlafaxine" OR "verapamil" OR "verteporfin" OR "warfarin" OR "whole-body irradiation" 
OR "wortmannin" OR "yohimbine" OR "zoledronate" OR "zopiclone" OR "zotepine" OR 
"zuclopenthixol" OR "4-HNE" OR "7-Ketocholesterol" OR "aflatoxin" OR "Aipysurus laevis 
venom" OR "amorimia exotropica" OR "anti-mouse-GBM sera" OR "AOPP-modified rat serum 
albumin" OR "apoferritin" OR "bee sting*" OR "beta-conglycinin" OR "bovine serum albumin" 
OR "cantharidin" OR "ceramide" OR "citrinin" OR "concanavalin A" OR "connective tissue 
growth factor" OR "cow milk processing" OR "CTGF" OR "cylindrospermopsin" OR 
"deoxynivalenol" OR "D-fructofuranosyl" OR "Endotoxin*" OR "Exotoxin*" OR "fumonisin 
B1" OR "homopolysaccharide" OR "indican" OR "indoxyl sulfate" OR "levan" OR 
"lipopolysaccharide" OR "lipopolysaccharide-induced" OR "L-NAME" OR "L-NNA" OR "lps-
induced" OR "monocrotaline" OR "monosodium urate crystal" OR "mycobacterial infection*" 
OR "Mycotoxin*" OR "nephritogenoside" OR "NG-nitro-L-arginine methyl ester" OR 
"Nitroarginine" OR "nivalenol" OR "Nω-nitro-L-arginine" OR "oak toxicosis" OR "ochratoxin 
A" OR "Ochratoxin*" OR "O-glycosylated IgA rheumatoid factor" OR "p-Cresyl sulfate" OR 
"PDGF-BB" OR "penicillic acid" OR "Platelet-derived growth factor-BB" OR "pufferfish 
tetrodotoxin" OR "quercus calliprinos" OR "scorpion sting*" OR "sea anemone Phyllodiscus 
semoni" OR "sea snake venom" OR "snake bite" OR "stinging insect venom" OR "tetrodotoxin" 
OR "Tityus serrulatus scorpion venom" OR "Tricothecene*" OR "U1-70-kDa small nuclear 
ribonucleoprotein/snRPN70" OR "viper snake venom" OR "vomitoxin" OR "wasp sting*" OR 
"yew" OR "*Bacteri*" OR "*Chia" OR "*Ococcus" OR "*Omonas" OR "adenine" OR 
"Aspergillus " OR "Bartonella henselae" OR "beta-hemolysin " OR "Brucella" OR 
"Burkholderia pseudomallei" OR "C. difficile toxin A" OR "C. difficile toxin B" OR 
"Campylobacter jejuni" OR "Campylobacter jejuni" OR "Candida albicans" OR "Candida 
tropicalis" OR "Candidemia" OR "Capillaria hepatica" OR "Chlamydia pneumoniae" OR 
"Chlamydia" OR "Chlamydophila" OR "Citrobacter rodentium" OR "Clostridium" OR 
"Corynebacterium diphtheriae" OR "diphtheria toxin" OR "Corynebacterium renale" OR 
"Dirofilaria immitis" OR "Echinococcus" OR "Ehrlichia canis" OR "Enterococcus faecalis" OR 
"Escherichia coli" OR "e. coli" OR "falciparum malaria" OR "malaria" OR "Fusarium 
graminearum" OR "Gemella haemolysans" OR "Haemophilus" OR "Helicobacter pylori" OR 
"Klebsiella pneumoniae" OR "leprosy" OR "Mycobacterium leprae" OR "Mycobacterium 
lepromatosis" OR "Leptospirosis" OR "leptospira" OR "marcescens" OR "Mycoplasma" OR 
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"Neisseria" OR "Nematode*" OR "Parasite*" OR "Penicillium aurantiogriseum" OR 
"Penicillium aurantiogriseum" OR "Plasmodium brasilianum" OR "Propionibacterium acnes" 
OR "Proteus mirabilis" OR "Pseudomonas aeruginosa" OR "Rickettsia" OR "Rochalimaea" OR 
"salmonella" OR "Schistosoma haematobium" OR "Schistosoma mansoni" OR "Serratia 
marcescens" OR "staphylococcal infection*" OR "Staphylococcus aureus" OR "Streptococcus 
agalactiae" OR "Streptococcus mutans" OR "Streptococcus pyogenes" OR "streptococcal 
pyrogenic exotoxin B" OR "Thy-1.1 monoclonal antibody" OR "Toxocara canis" OR 
"Treponema" OR "Trichinella spiralis" OR "Trypanosoma brucei" OR "Tyrophagus 
putrescentiae" OR "Vibrio" OR "Yersinia" OR "*OBACTER" OR "*nitrophenol*" OR 
"*benzene" OR "*ethane" OR "*phthalate" OR "*toluene" OR "1,1,1-trichloroethane" OR "12-
O-tetradecanoylphorbol-13-acetate " OR "1-methyl-4-phenylpyridinium" OR "2,3,5-
triiodobenzoic acid" OR "2,3,7,8-tetrachlorodibenzo-p-dioxin" OR "2-Amino-4-
(ethylthio)butyric acid) " OR "acetaldehyde" OR "acrolein" OR "Air pollutant*" OR "air 
pollution" OR "aldrin" OR "alloxan" OR "alpha-Naphthylisothiocyanate" OR "aluminium" OR 
"aluminum" OR "ammonium perchlorate" OR "anti-trinitrophenol switch variant mAbs" OR 
"arsenic" OR "asbestos" OR "asphalt" OR "atrazine" OR "beryllium" OR "Bis(2-ethylhexyl) 
phthalate" OR "bismuth" OR "bitumen" OR "bromodichloromethane" OR "bromoform" OR 
"cadmium" OR "carbon tetrachloride" OR "cedar dust" OR "cerium oxide nanoparticles" OR 
"chloroform" OR "chlorpyrifos" OR "chromic acid " OR "chromium" OR "copper sulphate " OR 
"copper" OR "cotton pellets" OR "cyromazine" OR "decabrom*" OR "DEHP" OR "diazinon" 
OR "dibromochloromethane" OR "dichloro*" OR "diesel" OR "diethylene glycol" OR 
"dimethylnitrosamine " OR "dinitro*" OR "dinitrochlorobenzene" OR "dioxane" OR "dioxin " 
OR "domestic gas" OR "ethionine " OR "ethylene dibromide " OR "ethylene glycol" OR 
"fiberglass" OR "fibreglass" OR "fluoro-10-methyl-1-2-benzanthracene " OR "formaldehyde" 
OR "gasoline" OR "germanium" OR "glycerol" OR "grain dust" OR "halomethane* " OR "hcy-
induced " OR "Heavy metal*" OR "Herbicide*" OR "hexabrom*" OR "hexachloro*" OR 
"hgcl2" OR "homocysteine" OR "house dust mite" OR "Hydrocarbons" OR "Insecticide*" OR 
"isopropyl alcohol" OR "jatropha curcas phorbol ester" OR "ketones" OR "malathion" OR 
"maleic vinyl ether anhydride " OR "Maneb" OR "melamine" OR "menadione sodium bisulfite" 
OR "mercuric chloride" OR "Mercury" OR "methyl tertiary-butyl ether " OR "methylene 
chloride" OR "methylglyoxal" OR "multiwalled carbon nanotube*" OR "N,N′-dimethyl-4,4′-
bipyridinium dichloride" OR "N,N'-diacetylbenzidine " OR "N-3-5-dichlorophenyl-succinimide" 
OR "nanocopper" OR "n-methyl-n 1-nitro-n-nitroso guanidine " OR "nonylphenol" OR 
"octylphenol" OR "oxalates" OR "oxidant-induced" OR "p-Aminophenol" OR "parachloro*" OR 
"paraphenylenediamine" OR "paraquat " OR "Particulates" OR "pb" OR "pentachloro*" OR 
"pentachlorophenol" OR "perchloroethylene" OR "perfluor*" OR "perfluoroalkyl chemicals" OR 
"perfluorooctane sulfonate" OR "perfluorooctanoic acid" OR "Pesticide*" OR "Phenols" OR 
"phenylenediamine " OR "picric acid" OR "plant growth regulator* " OR "polybrom*" OR 
"polychlor*" OR "polychlorinated organic compound* " OR "polyfluor*" OR "polymethyl 
methacrylate " OR "potassium bichromate " OR "pristane" OR "p-xylene" OR "pyrinuron" OR 
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"pyruvaldehyde " OR "silane " OR "silica" OR "silicon dioxide" OR "single wall carbon 
nanotube*" OR "styrene" OR "tetrabrom*" OR "tetrachloro*" OR "tetrachloroethylene" OR 
"thioacetamide " OR "titanium dioxide nanoparticles" OR "toluene" OR "trichloro*" OR 
"trichloroethylene" OR "trimethylpentane" OR "trinitrobenzenesulfonic acid " OR 
"Trinitrophenol" OR "uranium" OR "uranyl nitrate" OR "vacor" OR "wood dust" OR "wood 
preservatives" OR "xylene" OR "zinc phosphide" OR "sediment-associated" OR "particle-
associated" OR "traffic-related" OR "work-related" OR EMF) near/20 ("poison*" OR 
"ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR environmental OR 
"induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR "chemotherapy-caus*" 
OR "treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR "cytokine*-caus*" OR 
"surg*-caus*" OR "radiation-caus*" OR "steroid-caus*" OR "mechanically-caus*" OR "promot* 
progression" OR "caus* accumulation" OR "caus* * accumulation" OR "progression of" OR 
expos* OR contamina* OR chemicals OR abuse* OR induc* OR "long-term effect*" OR 
"inhibit* *protection" OR dysfunction* OR aggregation OR accumulation OR "disease link* to" 
OR "chemical initiator*" OR "stimulat* microglia" OR "activat* microglia" OR "increas* risk*" 
OR "increas* the risk*" OR "adverse event*" OR "adverse reaction*" OR "adverse * event*" OR 
"adverse * reaction" OR "adverse effect*" OR "adverse * effect*" OR hypersensitivity OR 
aggravat* OR exacerbat* OR detriment* OR "caus* *toxi*" OR "increas* *toxi" OR "produc* 
*toxi*" OR "enhanc* *toxi*" OR "stimulat* *toxi*" OR "accelerat* *toxi*" OR "caus* 
degrad*" OR "increas* degrad*" OR "caus* damag*" OR "increas* damag*" OR "caus* * 
*toxi*" OR "increas* * *toxi" OR "produc* * *toxi*" OR "enhanc* * *toxi*" OR "stimulat* * 
*toxi*" OR "accelerat* * *toxi*" OR "caus* * degrad*" OR "increas* * degrad*" OR "caus* * 
damag*" OR "increas* * damag*" OR "*toxi* caus* by" OR "*toxi* increas* by" OR "*toxi* 
produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* accelerat* by" OR 
"damag* caus* by" OR "*damag* increas* by" OR deleterious OR deteriorat* OR trigger* OR  
worsen* OR harm* OR hazard* OR "side-effect*" OR dangerous OR destructive OR injurious 
OR unsafe OR "increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* Abeta" OR 
"increas* senile plaque*" OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" 
OR "increas*total tau" OR "increas* phospho-tau" OR "increas* tau protein*" OR "increas* 
hyperphosphorylated tau" OR "increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR 
"enhanc* beta-amyloid" OR "enhanc* Abeta" OR "enhanc* senile plaque*" OR "enhanc* tau 
aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR "enhanc*total tau" OR "enhanc* 
phospho-tau" OR "enhanc* tau protein*" OR "enhanc* hyperphosphorylated tau" OR "enhanc* 
neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR "stimulat* beta-amyloid" OR 
"stimulat* Abeta" OR "stimulat* senile plaque*" OR "stimulat* tau aggregat*" OR "stimulat* T-
tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-tau" OR "stimulat* 
tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary tangle*" 
OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* Abeta" OR "elevat* senile 
plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total 
tau" OR "elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" 
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OR "elevat* neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR 
"induc* Abeta" OR "induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR 
"induc* P-tau" OR "induc*total tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR 
"induc* hyperphosphorylated tau" OR "induc* neurofibrillary tangle*" OR "produc* amyloid-
beta" OR "produc* beta-amyloid" OR "produc* Abeta" OR "produc* senile plaque*" OR 
"produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-tau" OR "produc*total tau" OR 
"produc* phospho-tau" OR "produc* tau protein*" OR "produc* hyperphosphorylated tau" OR 
"produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR "accelerat* beta-amyloid" 
OR "accelerat* Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau aggregat*" OR 
"accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* phospho-tau" 
OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* 
neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "Abeta 
induc* by" OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" 
OR "P-tau induc* by" OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* 
induc* by" OR "hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR 
"amyloid-beta produc* by" OR "beta-amyloid produc* by" OR "Abeta produc* by" OR "senile 
plaque* produc* by" OR "tau aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* 
by" OR "total tau produc* by" OR "phospho-tau produc* by" OR "tau protein* produc* by" OR 
"hyperphosphorylated tau produc* by" OR "neurofibrillary tangle* produc* by" OR "caus* 
Alzheimer*" OR "caus* dementia" OR "caus* cognitive decline" OR "caus* brain* decline" OR 
"caus* functional decline" OR "caus* memory decline" OR "caus* cognitive deficit*" OR 
"caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity deficit*" OR "caus* 
behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR "caus* 
neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR 
"caus* memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological 
impair*" OR "caus* mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" 
OR "caus* executive function impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" 
OR "caus* synaptic loss*" OR "caus* memory loss*" OR "caus* loss of memory" OR "caus* 
hearing loss*" OR "caus* volume loss*" OR "caus* Impair* face recognition" OR "caus* 
Impair* reasoning" OR "caus* Impair* judgment" OR "caus* Impair* problem solving" OR 
"caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" OR "caus* diabetes" 
OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* hypercholesterolemia" OR 
"caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR "induc* 
dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional 
decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language 
deficit*" OR "induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral 
deficit*" OR "induc* saccade deficit*" OR "induc* learning deficit*" OR "induc* 
neuropsychological deficit*" OR "induc* cognitive impair*" OR "induc* vascular impair*" OR 
"induc* memory impair*" OR "induc* neurogenesis impair*" OR "induc* neuropsychological 
impair*" OR "induc* mind impair*" OR "induc* functional impair*" OR "induc* learning 
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impair*" OR "induc* executive function impair*" OR "induc* cognitive loss*" OR "induc* 
neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss of 
memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face 
recognition" OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* 
Impair* problem solving" OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* 
neuropathology" OR "induc* diabetes" OR "induc* hypertension" OR "induc* high cholesterol" 
OR "induc* hypercholesterolemia" OR "induc* obesity" OR "induc* metabolic syndrome" OR 
"produc* Alzheimer*" OR "produc* dementia" OR "produc* cognitive decline" OR "produc* 
brain* decline" OR "produc* functional decline" OR "produc* memory decline" OR "produc* 
cognitive deficit*" OR "produc* language deficit*" OR "produc* memory deficit*" OR 
"produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade deficit*" 
OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* 
cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* 
neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" 
OR "produc* functional impair*" OR "produc* learning impair*" OR "produc* executive 
function impair*" OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* 
synaptic loss*" OR "produc* memory loss*" OR "produc* loss of memory" OR "produc* 
hearing loss*" OR "produc* volume loss*" OR "produc* Impair* face recognition" OR "produc* 
Impair* reasoning" OR "produc* Impair* judgment" OR "produc* Impair* problem solving" OR 
"produc* inflamm*" OR "produc* oxidative stress" OR "produc* neuropathology" OR "produc* 
diabetes" OR "produc* hypertension" OR "produc* high cholesterol" OR "produc* 
hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic syndrome" OR "increas* 
Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR "increas* brain* 
decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* 
cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR 
"increas* plasticity deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" 
OR "increas* learning deficit*" OR "increas* neuropsychological deficit*" OR "increas* 
cognitive impair*" OR "increas* vascular impair*" OR "increas* memory impair*" OR 
"increas* neurogenesis impair*" OR "increas* neuropsychological impair*" OR "increas* mind 
impair*" OR "increas* functional impair*" OR "increas* learning impair*" OR "increas* 
executive function impair*" OR "increas* cognitive loss*" OR "increas* neuronal loss*" OR 
"increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" OR 
"increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" 
OR "increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* 
problem solving" OR "increas* inflamm*" OR "increas* oxidative stress" OR "increas* 
neuropathology" OR "increas* diabetes" OR "increas* hypertension" OR "increas* high 
cholesterol" OR "increas* hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic 
syndrome" OR "exacerbat* Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive 
decline" OR "exacerbat* brain* decline" OR "exacerbat* functional decline" OR "exacerbat* 
memory decline" OR "exacerbat* cognitive deficit*" OR "exacerbat* language deficit*" OR 
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"exacerbat* memory deficit*" OR "exacerbat* plasticity deficit*" OR "exacerbat* behavioral 
deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning deficit*" OR "exacerbat* 
neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR "exacerbat* vascular 
impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" OR 
"exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* 
functional impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function 
impair*" OR "exacerbat* cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* 
synaptic loss*" OR "exacerbat* memory loss*" OR "exacerbat* loss of memory" OR 
"exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR "exacerbat* Impair* face 
recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* judgment" OR 
"exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* oxidative 
stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR 
"exacerbat* obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR 
"trigger* dementia" OR "trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* 
functional decline" OR "trigger* memory decline" OR "trigger* cognitive deficit*" OR "trigger* 
language deficit*" OR "trigger* memory deficit*" OR "trigger* plasticity deficit*" OR "trigger* 
behavioral deficit*" OR "trigger* saccade deficit*" OR "trigger* learning deficit*" OR "trigger* 
neuropsychological deficit*" OR "trigger* cognitive impair*" OR "trigger* vascular impair*" 
OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR "trigger* 
neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR 
"trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive 
loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" 
OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR 
"trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* 
judgment" OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* 
oxidative stress" OR "trigger* neuropathology" OR "trigger* diabetes" OR "trigger* 
hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* 
obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* 
dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* 
functional decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR 
"accelerat* language deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity 
deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR "accelerat* 
learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive 
impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* 
neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind 
impair*" OR "accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* 
executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR 
"accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR 
"accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face 
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recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR 
"accelerat* Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative 
stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" 
OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" 
OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" 
OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline caused 
by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* 
caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral 
deficit* caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR 
"neuropsychological deficit* caused by" OR "cognitive impair* caused by" OR "vascular 
impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused by" OR 
"neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* 
caused by" OR "learning impair* caused by" OR " executive function impair* caused by" OR 
"cognitive loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR 
"memory loss* caused by" OR "loss of memory caused by" OR "hearing loss* caused by" OR 
"volume loss* caused by" OR "Impair* face recognition caused by" OR "Impair* reasoning 
caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused by" OR 
"inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR 
"diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR 
"hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" 
OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" 
OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline 
induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR 
"memory deficit* induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* 
induced by" OR "saccade deficit* induced by" OR "learning deficit* induced by" OR 
"neuropsychological deficit* induced by" OR "cognitive impair* induced by" OR "vascular 
impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced by" 
OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional 
impair* induced by" OR "learning impair* induced by" OR " executive function impair* induced 
by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* 
induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing 
loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR 
"Impair* reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem 
solving induced by" OR "inflamm* induced by" OR "oxidative stress induced by" OR 
"neuropathology induced by" OR "diabetes induced by" OR "hypertension induced by" OR 
"high cholesterol induced by" OR "hypercholesterolemia induced by" OR "obesity induced by" 
OR "metabolic syndrome induced by")  
OR 
IIB. LIFESTYLE-SPECIFIC COMPONENT 
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IIB1. LIFESTYLE-SPECIFIC COMPONENT - TOPIC 
("2,3-Pentanedione" OR "acidogenic diet*" OR "acrylamide" OR "activity restriction" OR "acute 
stress" OR "additives" OR "advanced glycation end product*" OR "Advanced glycosylation end 
product*" OR "adverse food" OR "alcohol abuse*" OR "alcohol consum*" OR "alcohol intake" 
OR "alcoholic*" OR "alcohol-induc*" OR "alcoholism" OR "Amanita phalloides" OR 
"amphetamine*" OR "anabolic steroid*" OR "areca nut chewing" OR arnica OR "aspartame" OR 
"betel nut chewing" OR "binge eating" OR "biomass fuel for cooking" OR "bitter orange"   OR 
"caffeine" OR "childhood adversity" OR "chinese herb*" OR "chlorogenic acid" OR 
"cholesterol-induced" OR "cigarette*" OR "cocaine" OR "cola" OR "competitive strength 
exercise training" OR cortinarius OR "dehydration" OR "depression-caus*" OR "depression-
induc*" OR dextrose OR diet* near/1 effect* OR diet*-caus* OR diet*-induc* OR dietborne OR 
"djenkol beans" OR "early-life abuse" OR "eating fast" OR "effort-reward imbalance" OR 
"emotional abuse" OR ephedra OR "exercise-caus*" OR "folic acid-induc*" OR "food additive" 
OR "food poisoning" OR "free-fatty-acid-induced" OR "fructose" OR "germ-free" OR "glucose-
induc*" OR "glucose-peaks-short-term" OR "gluten" OR glycerin OR guarana OR "heat stroke" 
OR "heroin" OR "high home temperature" OR "high insulin" OR "high meat" OR "high 
selenium diet" OR "high-fat-diet*" OR "high-glucose-induc*" OR "High-glycemic-load diet*" 
OR "high-phosphate" OR "high-phosphorous-diet*" OR "high-protein-diet*" OR "high-protein-
induc*" OR "high-protein-intake*" OR "high-salt-diet*" OR "high-salt-intake*" OR "high-
saturated-fat diet*" OR "high-sodium-diet*" OR "high-sodium-intake*" OR "high-soybean oil" 
OR "high-sucrose-diet*" OR "high-sugar-diet*" OR "high-tryptophan-diet*" OR "Highway 
proximity" OR hypothermia OR "hypoxia-induced" OR "insufficient sleep" OR "job strain" OR 
"laxative abuse" OR "low fiber diet*" OR "low fiber intake" OR "low legumes intake" OR "low 
manganese intake" OR "low melatonin" OR "low potassium intake" OR "low pulses intake" OR 
"low-Vitamin D intake" OR "meat" OR "milk processing" OR "morphine" OR mothball* OR 
"mushrooms" OR noise OR "overfeeding" OR palmitate OR "palmitic acid" OR "parental 
hypertension" OR "parental occupation*" OR "parental sucrose" OR "persistent organic 
pollutants" OR "phosphorus additive*" OR "physical inactivity" OR "prenatal hypoxia" OR 
"preserved food*" OR "preserved meat*" OR "prolonged sitting" OR "psychogenic polydipsia" 
OR "psychological trauma" OR "refined carbohydrate*" OR "refined cereal*" OR "refined 
grain*" OR "refined flour" OR "residential remoteness" OR "salt-induced" OR "saturated fat*" 
OR "sedentary" OR "short sleep duration" OR "sitting time" OR "sleep deprivation" OR 
"smoking" OR "social environment" OR "sodium additive*" OR "soft drink*" OR "soybean oil 
heated repeatedly" OR "soy-rich diet" OR "star fruit" OR "sucralose" OR "sunflower oil" OR 
"tobacco" OR "trans-fat*" OR "water-borne" OR "zinc-deficient diet" OR low near/2 sunlight 
OR waterborne)  
OR 
IIB2. LIFESTYLE-SPECIFIC COMPONENT - TITLE 
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(diet* near/1 effect* OR "adverse food" OR "additives" OR exercise-induc* OR diet*-induc* 
OR exercise-caus*  OR diet*-caus* OR waterborne OR "water-borne" OR dietborne OR 
"acidogenic diet*" OR "activity restriction" OR "advanced glycation end product*" OR 
"Advanced glycosylation end product*" OR "alcohol abuse*" OR "alcohol consum*" OR 
"alcohol intake" OR "alcoholic*" OR "alcohol-induc*" OR "alcoholism" OR "amphetamine*" 
OR "anabolic steroid*" OR "areca nut chewing" OR "betel nut chewing" OR "binge eating" OR 
"caffeine" OR "childhood adversity" OR "chinese herb*" OR "cholesterol-induced" OR 
"cigarette*" OR "cocaine" OR "cola" OR "milk processing" OR "dehydration" OR "depression-
induc*" OR "depression-caus*" OR "effort-reward imbalance" OR "emotional abuse" OR 
"Exercise-induced" OR "folic acid-induc*" OR "free-fatty-acid-induced" OR "fructose" OR 
"germ-free" OR "glucose-induc*" OR "glucose-peaks-short-term" OR "gluten" OR "heat stroke" 
OR "heroin" OR "high-fat-diet*" OR "high-glucose-induc*" OR "High-glycemic-load diet*" OR 
"high home temperature" OR "high insulin" OR "high meat" OR "high-phosphate" OR "high-
phosphorous-diet*" OR "high-protein-diet*" OR "high-protein-intake*" OR "high-protein-
induc*" OR "high-salt-diet*" OR "high-salt-intake*" OR "high-saturated-fat diet*" OR "high 
selenium diet" OR "high-sodium-intake*" OR "high-sodium-diet*" OR "high-soybean oil" OR 
"high-sucrose-diet*" OR "high-tryptophan-diet*" OR "job strain" OR "laxative abuse" OR 
"psychological trauma" OR "competitive strength exercise training" OR "low fiber diet*" OR 
"low fiber intake" OR "low legumes intake" OR "low manganese intake" OR "low melatonin" 
OR "low potassium intake" OR "low pulses intake" OR "low-Vitamin D intake" OR "meat" OR 
"morphine" OR "mothball abuse" OR "mushrooms" OR "parental sucrose" OR "phosphorus 
additive*" OR "physical inactivity" OR "refined cereal*" OR "residential remoteness" OR "salt-
induced" OR "sedentary" OR "short sleep duration" OR "sitting time" OR "sleep deprivation" 
OR "smoking" OR "social environment" OR "sodium additive*" OR "soybean oil heated 
repeatedly" OR "soy-rich diet" OR "star fruit" OR "stress-induced" OR "sunflower oil" OR 
"tobacco" OR "overfeeding" OR "zinc-deficient diet" OR "TRANS-FAT*" OR "2,3-
Pentanedione" OR "acute stress" OR "biomass fuel for cooking" OR "early-life abuse" OR 
"Highway proximity" OR "parental occupation*" OR "Sugar" OR "Refined Carbohydrate*" OR 
"Acrylamide" OR "Aspartame" OR "Sucralose" OR "Preserved Meat*" OR "Refined Flour" OR 
"Saturated Fat*" OR "Soft Drink*" OR "Preserved Food*" OR "Insufficient Sleep") 
OR 
  
III. MESH FIELD TERMS 
RUN 3A1 AND 3B1 AS ONE QUERY 
IIIA. MESH QUALIFIERS - MESH HEADING 
IIIA1. NON-LIFESTYLE-SPECIFIC COMPONENT 
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(/"chemically induced" OR /toxicity OR /poisoning)  
OR 
IIIB. MESH GENERIC TERMS - MESH HEADING NO EXPLODE  
IIIB1. NON-LIFESTYLE-SPECIFIC COMPONENT - MESH HEADING NO EXPLODE 
Abnormalities, Drug-Induced OR Aids Related Opportunistic Infections OR Air Pollutants, 
Occupational OR Bacterial Infections OR Congenital Abnormalities OR Congenital Disorders 
Of Glycosylation OR Dermatitis, Occupational OR Drug Eruptions OR Drug Hypersensitivity 
OR Drug Toxicity OR Environmental Exposure OR Environmental Illness OR Environmental 
Monitoring OR Environmental Pollutants OR Fossil Fuels OR Hazardous Substances OR 
Herbicides OR Household Products OR HTLV I Infections OR Iatrogenic Disease OR Inhalation 
Exposure OR Insecticides OR Marine Toxins OR Maternal Exposure OR Mutagens OR 
Mycotoxins OR Neurotoxins OR Nonprescription Drugs OR Occupational Diseases OR 
Occupational Exposure OR Occupations OR Opportunistic Infections OR Organic Chemicals 
OR Paternal Exposure OR Pesticides OR Plant Poisoning OR Plants, Toxic OR Poisoning OR 
Poisons OR Prenatal Exposure Delayed Effects OR Simplexvirus OR Soil Pollutants OR 
Solvents OR Streptococcal Infections OR Vehicle Emissions OR Water Pollutants, Chemical OR 
Welding 
OR 
IIIB2. LIFESTYLE-SPECIFIC COMPONENT - MESH HEADING NO EXPLODE 
Alcohol Drinking OR Alcoholic Intoxication OR Alcoholism OR Alcohol-Related Disorders OR 
Amphetamine-Related Disorders OR Amphetamines OR Appetite Depressants OR Carbonated 
Beverages OR Cocaine OR Cocaine-Related Disorders OR Cola OR Contraceptive Agents OR 
Contraceptives, Oral OR Cooking And Eating Utensils OR Cosmetics OR Diet, High-Fat OR 
Fast Foods OR Food Additives OR Food Contamination OR Food Habits OR Food Preservatives 
OR Fructose OR Glycemic Index OR Glycosylation End Products, Advanced/adverse effects OR 
Hair Dyes OR Hallucinogens OR Hazardous Substances OR Heat Stroke OR Heroin OR Heroin 
Dependence OR Laxatives OR Leisure Activities OR Marijuana Abuse OR Methadone OR 
Mushroom Poisoning OR Narcotics OR Nonprescription Drugs OR Plant Poisoning OR Plants, 
Toxic OR Prenatal Exposure Delayed Effects OR Smoking OR Sodium Chloride, Dietary OR 
Sodium, Dietary OR Street Drugs OR Substance-Related Disorders OR Sweetening Agents OR 
Tattooing OR Tobacco OR Tobacco Smoke Pollution OR Tobacco Use Disorder OR Substance 
Withdrawal Syndrome OR Obesity OR Meat OR Foodborne Diseases OR Food Handling OR 
Dietary Fats OR Dietary Carbohydrates OR Plants Genetically Modified OR Sucrose OR 
Behavior Addictive OR Meat Products OR Poverty OR Maternal Exposure OR Flavoring Agents 
OR Diet High Fat OR Coffee OR Dairy Products OR Nutrition Disorders OR Prenatal Care OR 
Child Abuse OR Television OR Hygiene OR Doping In Sports OR Maternal Behavior OR 
Prevention and reversal of Alzheimer's disease: treatment protocol     Copyright © 2018     Kostoff et al 
 
 
Dietary Sucrose OR Thiamine Deficiency OR Folic Acid Deficiency OR Vitamin D Deficiency 
OR Cholesterol Dietary OR Lifestyle OR Sedentary Lifestyle OR Eating Disorders OR Sleep 
Disorders OR Paternal Exposure  
OR 
MESH TERMS DRUGS 
IIIB3a. TITLE 
("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR 
environmental OR "induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR 
"chemotherapy-caus*" OR "treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR 
"cytokine*-caus*" OR "surg*-caus*" OR "radiation-caus*" OR "steroid-caus*" OR 
"mechanically-caus*" OR "promot* progression" OR "caus* accumulation" OR "caus* * 
accumulation" OR "progression of" OR expos* OR contamina* OR abuse* OR induc* OR 
"long-term effect*" OR "inhibit* *protection" OR dysfunction* OR aggregation OR 
accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" OR 
"activat* microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR 
"adverse reaction*" OR "adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR 
"adverse * effect*" OR hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR "caus* 
*toxi*" OR "increas* *toxi" OR "produc* *toxi*" OR "enhanc* *toxi*" OR "stimulat* *toxi*" 
OR "accelerat* *toxi*" OR "caus* degrad*" OR "increas* degrad*" OR "caus* damag*" OR 
"increas* damag*" OR "caus* * *toxi*" OR "increas* * *toxi" OR "produc* * *toxi*" OR 
"enhanc* * *toxi*" OR "stimulat* * *toxi*" OR "accelerat* * *toxi*" OR "caus* * degrad*" OR 
"increas* * degrad*" OR "caus* * damag*" OR "increas* * damag*" OR "*toxi* caus* by" OR 
"*toxi* increas* by" OR "*toxi* produc* by" OR "*toxi* enhanc* by" OR "*toxi* stimulat* by" 
OR "*toxi* accelerat* by" OR "damag* caus* by" OR "*damag* increas* by" OR deleterious 
OR deteriorat* OR trigger* OR  worsen* OR harm* OR hazard* OR "side-effect*" OR 
dangerous OR destructive OR injurious OR unsafe) 
AND 
MESH HEADING NO EXPLODE 
Antineoplastic Agents OR Anticoagulants OR Antineoplastic Combined Chemotherapy 
Protocols OR Anti-Inflammatory Agents, Non-Steroidal OR Hypoglycemic Agents OR Anti-
Bacterial Agents OR Antipsychotic Agents OR Immunosuppressive Agents OR Anticonvulsants 
OR Platelet Aggregation Inhibitors OR Glucocorticoids OR Analgesics, Opioid OR Drug-
Related Side Effects and Adverse Reactions OR Warfarin OR Analgesics OR Doxorubicin OR 
Cisplatin OR Protein Kinase Inhibitors OR Fibrinolytic Agents OR Fluorouracil OR 
Antirheumatic Agents OR Antihypertensive Agents OR Pyridines OR Cyclophosphamide OR 
Bone Density Conservation Agents OR Antiviral Agents OR Bleomycin OR Antidepressive 
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Agents OR Serotonin Uptake Inhibitors OR Thiophenes OR Antibiotics, Antineoplastic OR 
Angiogenesis Inhibitors OR Drug Hypersensitivity OR Proton Pump Inhibitors OR 
Deoxycytidine OR Ticlopidine OR Organoplatinum Compounds OR Anti-Arrhythmia Agents 
OR Angiotensin-Converting Enzyme Inhibitors OR Anti-HIV Agents OR Paclitaxel OR 
Chemotherapy, Adjuvant OR Acetaminophen OR Quinazolines OR Taxoids OR Vasodilator 
Agents OR Pilocarpine OR Triazoles OR Benzodiazepines OR Anti-Infective Agents OR 
Estrogens OR Thiazolidinediones OR Antineoplastic Agents, Hormonal OR Antineoplastic 
Agents, Phytogenic OR Cyclooxygenase 2 Inhibitors OR  Anti-Ulcer Agents OR Cyclosporine 
OR Vasoconstrictor Agents OR Anthracyclines OR Anticarcinogenic Agents OR Convulsants 
OR Calcium Channel Blockers OR Cardiotonic Agents OR Dermatologic Agents OR 
Isoproterenol OR Antifungal Agents OR Ribavirin OR Antiparkinson Agents OR Clozapine OR 
Carboplatin OR Tamoxifen OR Antiretroviral Therapy, Highly Active OR Vincristine OR 
Cholinesterase Inhibitors OR Antidepressive Agents, Second-Generation OR Antitubercular 
Agents OR Hypolipidemic Agents OR Antineoplastic Agents, Alkylating OR Gastrointestinal 
Agents OR Aromatase Inhibitors OR Antithyroid Agents OR Organophosphonates OR 
Cyclooxygenase Inhibitors OR Antidepressive Agents, Tricyclic OR Antimanic Agents OR 
Phosphodiesterase 5 Inhibitors OR Dipeptidyl-Peptidase IV Inhibitors OR Anti-Retroviral 
Agents OR Methyl Ethers OR Chelating Agents OR Anticholesteremic Agents OR 
Contraceptive Agents, Female OR Anti-Asthmatic Agents OR Dopamine Uptake Inhibitors OR 
HIV Protease Inhibitors OR N-Methyl-3,4-methylenedioxyamphetamine OR Mycophenolic Acid 
OR Bronchodilator Agents OR Hydroxychloroquine OR Neurotransmitter Agents OR Anti-
Obesity Agents OR Anabolic Agents OR Anesthetics OR Cardiovascular Agents OR Histone 
Deacetylase Inhibitors OR Alkylating Agents OR Chloroquine OR Antifibrinolytic Agents OR 
Benzoxazines OR Protease Inhibitors OR Fertility Agents, Female OR Dopamine Agents OR 
Anti-Infective Agents, Local OR Reverse Transcriptase Inhibitors OR Neuromuscular Agents 
OR Anti-Allergic Agents OR Monoamine Oxidase Inhibitors OR Neuromuscular 
Nondepolarizing Agents OR Nootropic Agents OR Photosensitizing Agents OR 5-alpha 
Reductase Inhibitors OR Sweetening Agents OR Sensory System Agents OR Adrenergic Agents 
OR Adrenergic Uptake Inhibitors OR Indicators and Reagents OR Antitussive Agents OR 
Surface-Active Agents OR Antimutagenic Agents 
OR 
IIIB3b. TOPIC 
("increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* Abeta" OR "increas* senile 
plaque*" OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR 
"increas*total tau" OR "increas* phospho-tau" OR "increas* tau protein*" OR "increas* 
hyperphosphorylated tau" OR "increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR 
"enhanc* beta-amyloid" OR "enhanc* Abeta" OR "enhanc* senile plaque*" OR "enhanc* tau 
aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR "enhanc*total tau" OR "enhanc* 
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phospho-tau" OR "enhanc* tau protein*" OR "enhanc* hyperphosphorylated tau" OR "enhanc* 
neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR "stimulat* beta-amyloid" OR 
"stimulat* Abeta" OR "stimulat* senile plaque*" OR "stimulat* tau aggregat*" OR "stimulat* T-
tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-tau" OR "stimulat* 
tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary tangle*" 
OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* Abeta" OR "elevat* senile 
plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total 
tau" OR "elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" 
OR "elevat* neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR 
"induc* Abeta" OR "induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR 
"induc* P-tau" OR "induc*total tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR 
"induc* hyperphosphorylated tau" OR "induc* neurofibrillary tangle*" OR "produc* amyloid-
beta" OR "produc* beta-amyloid" OR "produc* Abeta" OR "produc* senile plaque*" OR 
"produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-tau" OR "produc*total tau" OR 
"produc* phospho-tau" OR "produc* tau protein*" OR "produc* hyperphosphorylated tau" OR 
"produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR "accelerat* beta-amyloid" 
OR "accelerat* Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau aggregat*" OR 
"accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* phospho-tau" 
OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* 
neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "Abeta 
induc* by" OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" 
OR "P-tau induc* by" OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* 
induc* by" OR "hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR 
"amyloid-beta produc* by" OR "beta-amyloid produc* by" OR "Abeta produc* by" OR "senile 
plaque* produc* by" OR "tau aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* 
by" OR "total tau produc* by" OR "phospho-tau produc* by" OR "tau protein* produc* by" OR 
"hyperphosphorylated tau produc* by" OR "neurofibrillary tangle* produc* by" OR "caus* 
Alzheimer*" OR "caus* dementia" OR "caus* cognitive decline" OR "caus* brain* decline" OR 
"caus* functional decline" OR "caus* memory decline" OR "caus* cognitive deficit*" OR 
"caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity deficit*" OR "caus* 
behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR "caus* 
neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR 
"caus* memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological 
impair*" OR "caus* mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" 
OR "caus* executive function impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" 
OR "caus* synaptic loss*" OR "caus* memory loss*" OR "caus* loss of memory" OR "caus* 
hearing loss*" OR "caus* volume loss*" OR "caus* Impair* face recognition" OR "caus* 
Impair* reasoning" OR "caus* Impair* judgment" OR "caus* Impair* problem solving" OR 
"caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" OR "caus* diabetes" 
OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* hypercholesterolemia" OR 
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"caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR "induc* 
dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional 
decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language 
deficit*" OR "induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral 
deficit*" OR "induc* saccade deficit*" OR "induc* learning deficit*" OR "induc* 
neuropsychological deficit*" OR "induc* cognitive impair*" OR "induc* vascular impair*" OR 
"induc* memory impair*" OR "induc* neurogenesis impair*" OR "induc* neuropsychological 
impair*" OR "induc* mind impair*" OR "induc* functional impair*" OR "induc* learning 
impair*" OR "induc* executive function impair*" OR "induc* cognitive loss*" OR "induc* 
neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss of 
memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face 
recognition" OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* 
Impair* problem solving" OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* 
neuropathology" OR "induc* diabetes" OR "induc* hypertension" OR "induc* high cholesterol" 
OR "induc* hypercholesterolemia" OR "induc* obesity" OR "induc* metabolic syndrome" OR 
"produc* Alzheimer*" OR "produc* dementia" OR "produc* cognitive decline" OR "produc* 
brain* decline" OR "produc* functional decline" OR "produc* memory decline" OR "produc* 
cognitive deficit*" OR "produc* language deficit*" OR "produc* memory deficit*" OR 
"produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade deficit*" 
OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* 
cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* 
neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" 
OR "produc* functional impair*" OR "produc* learning impair*" OR "produc* executive 
function impair*" OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* 
synaptic loss*" OR "produc* memory loss*" OR "produc* loss of memory" OR "produc* 
hearing loss*" OR "produc* volume loss*" OR "produc* Impair* face recognition" OR "produc* 
Impair* reasoning" OR "produc* Impair* judgment" OR "produc* Impair* problem solving" OR 
"produc* inflamm*" OR "produc* oxidative stress" OR "produc* neuropathology" OR "produc* 
diabetes" OR "produc* hypertension" OR "produc* high cholesterol" OR "produc* 
hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic syndrome" OR "increas* 
Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR "increas* brain* 
decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* 
cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR 
"increas* plasticity deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" 
OR "increas* learning deficit*" OR "increas* neuropsychological deficit*" OR "increas* 
cognitive impair*" OR "increas* vascular impair*" OR "increas* memory impair*" OR 
"increas* neurogenesis impair*" OR "increas* neuropsychological impair*" OR "increas* mind 
impair*" OR "increas* functional impair*" OR "increas* learning impair*" OR "increas* 
executive function impair*" OR "increas* cognitive loss*" OR "increas* neuronal loss*" OR 
"increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" OR 
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"increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" 
OR "increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* 
problem solving" OR "increas* inflamm*" OR "increas* oxidative stress" OR "increas* 
neuropathology" OR "increas* diabetes" OR "increas* hypertension" OR "increas* high 
cholesterol" OR "increas* hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic 
syndrome" OR "exacerbat* Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive 
decline" OR "exacerbat* brain* decline" OR "exacerbat* functional decline" OR "exacerbat* 
memory decline" OR "exacerbat* cognitive deficit*" OR "exacerbat* language deficit*" OR 
"exacerbat* memory deficit*" OR "exacerbat* plasticity deficit*" OR "exacerbat* behavioral 
deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning deficit*" OR "exacerbat* 
neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR "exacerbat* vascular 
impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" OR 
"exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* 
functional impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function 
impair*" OR "exacerbat* cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* 
synaptic loss*" OR "exacerbat* memory loss*" OR "exacerbat* loss of memory" OR 
"exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR "exacerbat* Impair* face 
recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* judgment" OR 
"exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* oxidative 
stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR 
"exacerbat* obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR 
"trigger* dementia" OR "trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* 
functional decline" OR "trigger* memory decline" OR "trigger* cognitive deficit*" OR "trigger* 
language deficit*" OR "trigger* memory deficit*" OR "trigger* plasticity deficit*" OR "trigger* 
behavioral deficit*" OR "trigger* saccade deficit*" OR "trigger* learning deficit*" OR "trigger* 
neuropsychological deficit*" OR "trigger* cognitive impair*" OR "trigger* vascular impair*" 
OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR "trigger* 
neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR 
"trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive 
loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" 
OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR 
"trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* 
judgment" OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* 
oxidative stress" OR "trigger* neuropathology" OR "trigger* diabetes" OR "trigger* 
hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* 
obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* 
dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* 
functional decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR 
"accelerat* language deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity 
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deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR "accelerat* 
learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive 
impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* 
neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind 
impair*" OR "accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* 
executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR 
"accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR 
"accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face 
recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR 
"accelerat* Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative 
stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" 
OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" 
OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" 
OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline caused 
by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* 
caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral 
deficit* caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR 
"neuropsychological deficit* caused by" OR "cognitive impair* caused by" OR "vascular 
impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused by" OR 
"neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* 
caused by" OR "learning impair* caused by" OR " executive function impair* caused by" OR 
"cognitive loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR 
"memory loss* caused by" OR "loss of memory caused by" OR "hearing loss* caused by" OR 
"volume loss* caused by" OR "Impair* face recognition caused by" OR "Impair* reasoning 
caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused by" OR 
"inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR 
"diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR 
"hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" 
OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" 
OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline 
induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR 
"memory deficit* induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* 
induced by" OR "saccade deficit* induced by" OR "learning deficit* induced by" OR 
"neuropsychological deficit* induced by" OR "cognitive impair* induced by" OR "vascular 
impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced by" 
OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional 
impair* induced by" OR "learning impair* induced by" OR " executive function impair* induced 
by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* 
induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing 
loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR 
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"Impair* reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem 
solving induced by" OR "inflamm* induced by" OR "oxidative stress induced by" OR 
"neuropathology induced by" OR "diabetes induced by" OR "hypertension induced by" OR 
"high cholesterol induced by" OR "hypercholesterolemia induced by" OR "obesity induced by" 
OR "metabolic syndrome induced by") 
AND 
MESH HEADING NO EXPLODE 
Antineoplastic Agents OR Anticoagulants OR Antineoplastic Combined Chemotherapy 
Protocols OR Anti-Inflammatory Agents, Non-Steroidal OR Hypoglycemic Agents OR Anti-
Bacterial Agents OR Antipsychotic Agents OR Immunosuppressive Agents OR Anticonvulsants 
OR Platelet Aggregation Inhibitors OR Glucocorticoids OR Analgesics, Opioid OR Drug-
Related Side Effects and Adverse Reactions OR Warfarin OR Analgesics OR Doxorubicin OR 
Cisplatin OR Protein Kinase Inhibitors OR Fibrinolytic Agents OR Fluorouracil OR 
Antirheumatic Agents OR Antihypertensive Agents OR Pyridines OR Cyclophosphamide OR 
Bone Density Conservation Agents OR Antiviral Agents OR Bleomycin OR Antidepressive 
Agents OR Serotonin Uptake Inhibitors OR Thiophenes OR Antibiotics, Antineoplastic OR 
Angiogenesis Inhibitors OR Drug Hypersensitivity OR Proton Pump Inhibitors OR 
Deoxycytidine OR Ticlopidine OR Organoplatinum Compounds OR Anti-Arrhythmia Agents 
OR Angiotensin-Converting Enzyme Inhibitors OR Anti-HIV Agents OR Paclitaxel OR 
Chemotherapy, Adjuvant OR Acetaminophen OR Quinazolines OR Taxoids OR Vasodilator 
Agents OR Pilocarpine OR Triazoles OR Benzodiazepines OR Anti-Infective Agents OR 
Estrogens OR Thiazolidinediones OR Antineoplastic Agents, Hormonal OR Antineoplastic 
Agents, Phytogenic OR Cyclooxygenase 2 Inhibitors OR  Anti-Ulcer Agents OR Cyclosporine 
OR Vasoconstrictor Agents OR Anthracyclines OR Anticarcinogenic Agents OR Convulsants 
OR Calcium Channel Blockers OR Cardiotonic Agents OR Dermatologic Agents OR 
Isoproterenol OR Antifungal Agents OR Ribavirin OR Antiparkinson Agents OR Clozapine OR 
Carboplatin OR Tamoxifen OR Antiretroviral Therapy, Highly Active OR Vincristine OR 
Cholinesterase Inhibitors OR Antidepressive Agents, Second-Generation OR Antitubercular 
Agents OR Hypolipidemic Agents OR Antineoplastic Agents, Alkylating OR Gastrointestinal 
Agents OR Aromatase Inhibitors OR Antithyroid Agents OR Organophosphonates OR 
Cyclooxygenase Inhibitors OR Antidepressive Agents, Tricyclic OR Antimanic Agents OR 
Phosphodiesterase 5 Inhibitors OR Dipeptidyl-Peptidase IV Inhibitors OR Anti-Retroviral 
Agents OR Methyl Ethers OR Chelating Agents OR Anticholesteremic Agents OR 
Contraceptive Agents, Female OR Anti-Asthmatic Agents OR Dopamine Uptake Inhibitors OR 
HIV Protease Inhibitors OR N-Methyl-3,4-methylenedioxyamphetamine OR Mycophenolic Acid 
OR Bronchodilator Agents OR Hydroxychloroquine OR Neurotransmitter Agents OR Anti-
Obesity Agents OR Anabolic Agents OR Anesthetics OR Cardiovascular Agents OR Histone 
Deacetylase Inhibitors OR Alkylating Agents OR Chloroquine OR Antifibrinolytic Agents OR 
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Benzoxazines OR Protease Inhibitors OR Fertility Agents, Female OR Dopamine Agents OR 
Anti-Infective Agents, Local OR Reverse Transcriptase Inhibitors OR Neuromuscular Agents 
OR Anti-Allergic Agents OR Monoamine Oxidase Inhibitors OR Neuromuscular 
Nondepolarizing Agents OR Nootropic Agents OR Photosensitizing Agents OR 5-alpha 
Reductase Inhibitors OR Sweetening Agents OR Sensory System Agents OR Adrenergic Agents 
OR Adrenergic Uptake Inhibitors OR Indicators and Reagents OR Antitussive Agents OR 
Surface-Active Agents OR Antimutagenic Agents 
OR 
MESH TERMS CHEMICALS 
IIIB4a - TITLE 
("poison*" OR "ecotoxologic* effect*" OR "occupation*" OR pollut* OR "*virus*" OR 
environmental OR "induc*" OR "damage-caus*" OR "drug*-caus*" OR "infect*-caus*" OR 
"chemotherapy-caus*" OR "treat*-caus*" OR "anesthesia-caus*" OR "chemical*-caus*" OR 
"cytokine*-caus*" OR "surg*-caus*" OR "radiation-caus*" OR "steroid-caus*" OR 
"mechanically-caus*" OR "promot* progression" OR "caus* accumulation" OR "caus* * 
accumulation" OR "progression of" OR expos* OR contamina* OR chemicals OR abuse* OR 
induc* OR "long-term effect*" OR "inhibit* *protection" OR dysfunction* OR aggregation OR 
accumulation OR "disease link* to" OR "chemical initiator*" OR "stimulat* microglia" OR 
"activat* microglia" OR "increas* risk*" OR "increas* the risk*" OR "adverse event*" OR 
"adverse reaction*" OR "adverse * event*" OR "adverse * reaction" OR "adverse effect*" OR 
"adverse * effect*" OR hypersensitivity OR aggravat* OR exacerbat* OR detriment* OR 
*TOXI* OR "caus* * degrad*" OR "increas* * degrad*" OR "caus* * damag*" OR "increas* * 
damag*" OR "*toxi* caus* by" OR "*toxi* increas* by" OR "*toxi* produc* by" OR "*toxi* 
enhanc* by" OR "*toxi* stimulat* by" OR "*toxi* accelerat* by" OR "damag* caus* by" OR 
"*damag* increas* by" OR deleterious OR deteriorat* OR trigger* OR  worsen* OR harm* OR 
hazard* OR "side-effect*" OR dangerous OR destructive OR injurious OR unsafe)  
AND 
MESH HEADING NO EXPLODE 
Lipopolysaccharides OR Malondialdehyde OR Neurotoxicity Syndromes OR Carbon 
Tetrachloride OR Formaldehyde OR 9,10-Dimethyl-1,2-benzanthracene OR 
Trinitrobenzenesulfonic Acid OR Insecticides OR Endocrine Disruptors OR Diethylnitrosamine 
OR Hydrogen Peroxide OR Benzhydryl Compounds OR Chemical Warfare Agents OR Asbestos 
OR Herbicides OR Organometallic Compounds OR Scopolamine Hydrobromide OR Silicon 
Dioxide OR Polychlorinated Biphenyls OR 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine OR 
Benzo(a)pyrene OR Fluorocarbons OR Nitrogen Dioxide OR Polycyclic Hydrocarbons, 
Aromatic OR Tetrachlorodibenzodioxin OR Metals, Heavy OR Hydrocarbons, Chlorinated OR 
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Chemical Industry OR 1,2-Dimethylhydrazine OR Ethylene Glycol OR Nitrosamines OR 
Benzene OR Fluorides OR Agricultural Workers' Diseases OR Bromodeoxyuridine OR 
Chromium OR Organophosphorus Compounds OR Organic Chemicals OR Carbon Monoxide 
OR Benzalkonium Compounds OR Chlorpyrifos OR Organophosphates OR Organophosphate 
Poisoning OR Volatile Organic Compounds OR Diethylhexyl Phthalate OR Sulfur Dioxide OR 
Petroleum OR Methylmercury Compounds OR Chlorine OR Dichlorodiphenyl Dichloroethylene 
OR Hydrocarbons OR Trichloroethylene OR Carbon Tetrachloride Poisoning OR 3,4-
Dihydroxyphenylacetic Acid OR Alkanesulfonic Acids OR Plasticizers OR Halogenated 
Diphenyl Ethers OR Benzene Derivatives OR Dinitrofluorobenzene OR Toluene 2,4-
Diisocyanate OR Benzopyrenes OR Cyclohexenes OR Nitrobenzenes OR Plastics OR 
Trihalomethanes OR Hydrocarbons, Brominated 
OR 
IIIB4b. TOPIC 
 ("increas* amyloid-beta" OR "increas* beta-amyloid" OR "increas* Abeta" OR "increas* senile 
plaque*" OR "increas* tau aggregat*" OR "increas* T-tau" OR "increas* P-tau" OR 
"increas*total tau" OR "increas* phospho-tau" OR "increas* tau protein*" OR "increas* 
hyperphosphorylated tau" OR "increas* neurofibrillary tangle*" OR "enhanc* amyloid-beta" OR 
"enhanc* beta-amyloid" OR "enhanc* Abeta" OR "enhanc* senile plaque*" OR "enhanc* tau 
aggregat*" OR "enhanc* T-tau" OR "enhanc* P-tau" OR "enhanc*total tau" OR "enhanc* 
phospho-tau" OR "enhanc* tau protein*" OR "enhanc* hyperphosphorylated tau" OR "enhanc* 
neurofibrillary tangle*" OR "stimulat* amyloid-beta" OR "stimulat* beta-amyloid" OR 
"stimulat* Abeta" OR "stimulat* senile plaque*" OR "stimulat* tau aggregat*" OR "stimulat* T-
tau" OR "stimulat* P-tau" OR "stimulat*total tau" OR "stimulat* phospho-tau" OR "stimulat* 
tau protein*" OR "stimulat* hyperphosphorylated tau" OR "stimulat* neurofibrillary tangle*" 
OR "elevat* amyloid-beta" OR "elevat* beta-amyloid" OR "elevat* Abeta" OR "elevat* senile 
plaque*" OR "elevat* tau aggregat*" OR "elevat* T-tau" OR "elevat* P-tau" OR "elevat*total 
tau" OR "elevat* phospho-tau" OR "elevat* tau protein*" OR "elevat* hyperphosphorylated tau" 
OR "elevat* neurofibrillary tangle*" OR "induc* amyloid-beta" OR "induc* beta-amyloid" OR 
"induc* Abeta" OR "induc* senile plaque*" OR "induc* tau aggregat*" OR "induc* T-tau" OR 
"induc* P-tau" OR "induc*total tau" OR "induc* phospho-tau" OR "induc* tau protein*" OR 
"induc* hyperphosphorylated tau" OR "induc* neurofibrillary tangle*" OR "produc* amyloid-
beta" OR "produc* beta-amyloid" OR "produc* Abeta" OR "produc* senile plaque*" OR 
"produc* tau aggregat*" OR "produc* T-tau" OR "produc* P-tau" OR "produc*total tau" OR 
"produc* phospho-tau" OR "produc* tau protein*" OR "produc* hyperphosphorylated tau" OR 
"produc* neurofibrillary tangle*" OR "accelerat* amyloid-beta" OR "accelerat* beta-amyloid" 
OR "accelerat* Abeta" OR "accelerat* senile plaque*" OR "accelerat* tau aggregat*" OR 
"accelerat* T-tau" OR "accelerat* P-tau" OR "accelerat*total tau" OR "accelerat* phospho-tau" 
OR "accelerat* tau protein*" OR "accelerat* hyperphosphorylated tau" OR "accelerat* 
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neurofibrillary tangle*" OR "amyloid-beta induc* by" OR "beta-amyloid induc* by" OR "Abeta 
induc* by" OR "senile plaque* induc* by" OR "tau aggregat* induc* by" OR "T-tau induc* by" 
OR "P-tau induc* by" OR "total tau induc* by" OR "phospho-tau induc* by" OR "tau protein* 
induc* by" OR "hyperphosphorylated tau induc* by" OR "neurofibrillary tangle* induc* by" OR 
"amyloid-beta produc* by" OR "beta-amyloid produc* by" OR "Abeta produc* by" OR "senile 
plaque* produc* by" OR "tau aggregat* produc* by" OR "T-tau produc* by" OR "P-tau produc* 
by" OR "total tau produc* by" OR "phospho-tau produc* by" OR "tau protein* produc* by" OR 
"hyperphosphorylated tau produc* by" OR "neurofibrillary tangle* produc* by" OR "caus* 
Alzheimer*" OR "caus* dementia" OR "caus* cognitive decline" OR "caus* brain* decline" OR 
"caus* functional decline" OR "caus* memory decline" OR "caus* cognitive deficit*" OR 
"caus* language deficit*" OR "caus* memory deficit*" OR "caus* plasticity deficit*" OR "caus* 
behavioral deficit*" OR "caus* saccade deficit*" OR "caus* learning deficit*" OR "caus* 
neuropsychological deficit*" OR "caus* cognitive impair*" OR "caus* vascular impair*" OR 
"caus* memory impair*" OR "caus* neurogenesis impair*" OR "caus* neuropsychological 
impair*" OR "caus* mind impair*" OR "caus* functional impair*" OR "caus* learning impair*" 
OR "caus* executive function impair*" OR "caus* cognitive loss*" OR "caus* neuronal loss*" 
OR "caus* synaptic loss*" OR "caus* memory loss*" OR "caus* loss of memory" OR "caus* 
hearing loss*" OR "caus* volume loss*" OR "caus* Impair* face recognition" OR "caus* 
Impair* reasoning" OR "caus* Impair* judgment" OR "caus* Impair* problem solving" OR 
"caus* inflamm*" OR "caus* oxidative stress" OR "caus* neuropathology" OR "caus* diabetes" 
OR "caus* hypertension" OR "caus* high cholesterol" OR "caus* hypercholesterolemia" OR 
"caus* obesity" OR "caus* metabolic syndrome" OR "induc* Alzheimer*" OR "induc* 
dementia" OR "induc* cognitive decline" OR "induc* brain* decline" OR "induc* functional 
decline" OR "induc* memory decline" OR "induc* cognitive deficit*" OR "induc* language 
deficit*" OR "induc* memory deficit*" OR "induc* plasticity deficit*" OR "induc* behavioral 
deficit*" OR "induc* saccade deficit*" OR "induc* learning deficit*" OR "induc* 
neuropsychological deficit*" OR "induc* cognitive impair*" OR "induc* vascular impair*" OR 
"induc* memory impair*" OR "induc* neurogenesis impair*" OR "induc* neuropsychological 
impair*" OR "induc* mind impair*" OR "induc* functional impair*" OR "induc* learning 
impair*" OR "induc* executive function impair*" OR "induc* cognitive loss*" OR "induc* 
neuronal loss*" OR "induc* synaptic loss*" OR "induc* memory loss*" OR "induc* loss of 
memory" OR "induc* hearing loss*" OR "induc* volume loss*" OR "induc* Impair* face 
recognition" OR "induc* Impair* reasoning" OR "induc* Impair* judgment" OR "induc* 
Impair* problem solving" OR "induc* inflamm*" OR "induc* oxidative stress" OR "induc* 
neuropathology" OR "induc* diabetes" OR "induc* hypertension" OR "induc* high cholesterol" 
OR "induc* hypercholesterolemia" OR "induc* obesity" OR "induc* metabolic syndrome" OR 
"produc* Alzheimer*" OR "produc* dementia" OR "produc* cognitive decline" OR "produc* 
brain* decline" OR "produc* functional decline" OR "produc* memory decline" OR "produc* 
cognitive deficit*" OR "produc* language deficit*" OR "produc* memory deficit*" OR 
"produc* plasticity deficit*" OR "produc* behavioral deficit*" OR "produc* saccade deficit*" 
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OR "produc* learning deficit*" OR "produc* neuropsychological deficit*" OR "produc* 
cognitive impair*" OR "produc* vascular impair*" OR "produc* memory impair*" OR "produc* 
neurogenesis impair*" OR "produc* neuropsychological impair*" OR "produc* mind impair*" 
OR "produc* functional impair*" OR "produc* learning impair*" OR "produc* executive 
function impair*" OR "produc* cognitive loss*" OR "produc* neuronal loss*" OR "produc* 
synaptic loss*" OR "produc* memory loss*" OR "produc* loss of memory" OR "produc* 
hearing loss*" OR "produc* volume loss*" OR "produc* Impair* face recognition" OR "produc* 
Impair* reasoning" OR "produc* Impair* judgment" OR "produc* Impair* problem solving" OR 
"produc* inflamm*" OR "produc* oxidative stress" OR "produc* neuropathology" OR "produc* 
diabetes" OR "produc* hypertension" OR "produc* high cholesterol" OR "produc* 
hypercholesterolemia" OR "produc* obesity" OR "produc* metabolic syndrome" OR "increas* 
Alzheimer*" OR "increas* dementia" OR "increas* cognitive decline" OR "increas* brain* 
decline" OR "increas* functional decline" OR "increas* memory decline" OR "increas* 
cognitive deficit*" OR "increas* language deficit*" OR "increas* memory deficit*" OR 
"increas* plasticity deficit*" OR "increas* behavioral deficit*" OR "increas* saccade deficit*" 
OR "increas* learning deficit*" OR "increas* neuropsychological deficit*" OR "increas* 
cognitive impair*" OR "increas* vascular impair*" OR "increas* memory impair*" OR 
"increas* neurogenesis impair*" OR "increas* neuropsychological impair*" OR "increas* mind 
impair*" OR "increas* functional impair*" OR "increas* learning impair*" OR "increas* 
executive function impair*" OR "increas* cognitive loss*" OR "increas* neuronal loss*" OR 
"increas* synaptic loss*" OR "increas* memory loss*" OR "increas* loss of memory" OR 
"increas* hearing loss*" OR "increas* volume loss*" OR "increas* Impair* face recognition" 
OR "increas* Impair* reasoning" OR "increas* Impair* judgment" OR "increas* Impair* 
problem solving" OR "increas* inflamm*" OR "increas* oxidative stress" OR "increas* 
neuropathology" OR "increas* diabetes" OR "increas* hypertension" OR "increas* high 
cholesterol" OR "increas* hypercholesterolemia" OR "increas* obesity" OR "increas* metabolic 
syndrome" OR "exacerbat* Alzheimer*" OR "exacerbat* dementia" OR "exacerbat* cognitive 
decline" OR "exacerbat* brain* decline" OR "exacerbat* functional decline" OR "exacerbat* 
memory decline" OR "exacerbat* cognitive deficit*" OR "exacerbat* language deficit*" OR 
"exacerbat* memory deficit*" OR "exacerbat* plasticity deficit*" OR "exacerbat* behavioral 
deficit*" OR "exacerbat* saccade deficit*" OR "exacerbat* learning deficit*" OR "exacerbat* 
neuropsychological deficit*" OR "exacerbat* cognitive impair*" OR "exacerbat* vascular 
impair*" OR "exacerbat* memory impair*" OR "exacerbat* neurogenesis impair*" OR 
"exacerbat* neuropsychological impair*" OR "exacerbat* mind impair*" OR "exacerbat* 
functional impair*" OR "exacerbat* learning impair*" OR "exacerbat* executive function 
impair*" OR "exacerbat* cognitive loss*" OR "exacerbat* neuronal loss*" OR "exacerbat* 
synaptic loss*" OR "exacerbat* memory loss*" OR "exacerbat* loss of memory" OR 
"exacerbat* hearing loss*" OR "exacerbat* volume loss*" OR "exacerbat* Impair* face 
recognition" OR "exacerbat* Impair* reasoning" OR "exacerbat* Impair* judgment" OR 
"exacerbat* Impair* problem solving" OR "exacerbat* inflamm*" OR "exacerbat* oxidative 
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stress" OR "exacerbat* neuropathology" OR "exacerbat* diabetes" OR "exacerbat* 
hypertension" OR "exacerbat* high cholesterol" OR "exacerbat* hypercholesterolemia" OR 
"exacerbat* obesity" OR "exacerbat* metabolic syndrome" OR "trigger* Alzheimer*" OR 
"trigger* dementia" OR "trigger* cognitive decline" OR "trigger* brain* decline" OR "trigger* 
functional decline" OR "trigger* memory decline" OR "trigger* cognitive deficit*" OR "trigger* 
language deficit*" OR "trigger* memory deficit*" OR "trigger* plasticity deficit*" OR "trigger* 
behavioral deficit*" OR "trigger* saccade deficit*" OR "trigger* learning deficit*" OR "trigger* 
neuropsychological deficit*" OR "trigger* cognitive impair*" OR "trigger* vascular impair*" 
OR "trigger* memory impair*" OR "trigger* neurogenesis impair*" OR "trigger* 
neuropsychological impair*" OR "trigger* mind impair*" OR "trigger* functional impair*" OR 
"trigger* learning impair*" OR "trigger* executive function impair*" OR "trigger* cognitive 
loss*" OR "trigger* neuronal loss*" OR "trigger* synaptic loss*" OR "trigger* memory loss*" 
OR "trigger* loss of memory" OR "trigger* hearing loss*" OR "trigger* volume loss*" OR 
"trigger* Impair* face recognition" OR "trigger* Impair* reasoning" OR "trigger* Impair* 
judgment" OR "trigger* Impair* problem solving" OR "trigger* inflamm*" OR "trigger* 
oxidative stress" OR "trigger* neuropathology" OR "trigger* diabetes" OR "trigger* 
hypertension" OR "trigger* high cholesterol" OR "trigger* hypercholesterolemia" OR "trigger* 
obesity" OR "trigger* metabolic syndrome" OR "accelerat* Alzheimer*" OR "accelerat* 
dementia" OR "accelerat* cognitive decline" OR "accelerat* brain* decline" OR "accelerat* 
functional decline" OR "accelerat* memory decline" OR "accelerat* cognitive deficit*" OR 
"accelerat* language deficit*" OR "accelerat* memory deficit*" OR "accelerat* plasticity 
deficit*" OR "accelerat* behavioral deficit*" OR "accelerat* saccade deficit*" OR "accelerat* 
learning deficit*" OR "accelerat* neuropsychological deficit*" OR "accelerat* cognitive 
impair*" OR "accelerat* vascular impair*" OR "accelerat* memory impair*" OR "accelerat* 
neurogenesis impair*" OR "accelerat* neuropsychological impair*" OR "accelerat* mind 
impair*" OR "accelerat* functional impair*" OR "accelerat* learning impair*" OR "accelerat* 
executive function impair*" OR "accelerat* cognitive loss*" OR "accelerat* neuronal loss*" OR 
"accelerat* synaptic loss*" OR "accelerat* memory loss*" OR "accelerat* loss of memory" OR 
"accelerat* hearing loss*" OR "accelerat* volume loss*" OR "accelerat* Impair* face 
recognition" OR "accelerat* Impair* reasoning" OR "accelerat* Impair* judgment" OR 
"accelerat* Impair* problem solving" OR "accelerat* inflamm*" OR "accelerat* oxidative 
stress" OR "accelerat* neuropathology" OR "accelerat* diabetes" OR "accelerat* hypertension" 
OR "accelerat* high cholesterol" OR "accelerat* hypercholesterolemia" OR "accelerat* obesity" 
OR "accelerat* metabolic syndrome" OR "Alzheimer* * caused by" OR "dementia caused by" 
OR "cognitive decline caused by" OR "brain* decline caused by" OR "functional decline caused 
by" OR "memory decline caused by" OR "cognitive deficit* caused by" OR "language deficit* 
caused by" OR "memory deficit* caused by" OR "plasticity deficit* caused by" OR "behavioral 
deficit* caused by" OR "saccade deficit* caused by" OR "learning deficit* caused by" OR 
"neuropsychological deficit* caused by" OR "cognitive impair* caused by" OR "vascular 
impair* caused by" OR "memory impair* caused by" OR "neurogenesis impair* caused by" OR 
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"neuropsychological impair* caused by" OR "mind impair* caused by" OR "functional impair* 
caused by" OR "learning impair* caused by" OR " executive function impair* caused by" OR 
"cognitive loss* caused by" OR "neuronal loss* caused by" OR "synaptic loss* caused by" OR 
"memory loss* caused by" OR "loss of memory caused by" OR "hearing loss* caused by" OR 
"volume loss* caused by" OR "Impair* face recognition caused by" OR "Impair* reasoning 
caused by" OR "Impair* judgment caused by" OR "Impair* problem solving caused by" OR 
"inflamm* caused by" OR "oxidative stress caused by" OR "neuropathology caused by" OR 
"diabetes caused by" OR "hypertension caused by" OR "high cholesterol caused by" OR 
"hypercholesterolemia caused by" OR "obesity caused by" OR "metabolic syndrome caused by" 
OR "Alzheimer* * induced by" OR "dementia induced by" OR "cognitive decline induced by" 
OR "brain* decline induced by" OR "functional decline induced by" OR "memory decline 
induced by" OR "cognitive deficit* induced by" OR "language deficit* induced by" OR 
"memory deficit* induced by" OR "plasticity deficit* induced by" OR "behavioral deficit* 
induced by" OR "saccade deficit* induced by" OR "learning deficit* induced by" OR 
"neuropsychological deficit* induced by" OR "cognitive impair* induced by" OR "vascular 
impair* induced by" OR "memory impair* induced by" OR "neurogenesis impair* induced by" 
OR "neuropsychological impair* induced by" OR "mind impair* induced by" OR "functional 
impair* induced by" OR "learning impair* induced by" OR " executive function impair* induced 
by" OR "cognitive loss* induced by" OR "neuronal loss* induced by" OR "synaptic loss* 
induced by" OR "memory loss* induced by" OR "loss of memory induced by" OR "hearing 
loss* induced by" OR "volume loss* induced by" OR "Impair* face recognition induced by" OR 
"Impair* reasoning induced by" OR "Impair* judgment induced by" OR "Impair* problem 
solving induced by" OR "inflamm* induced by" OR "oxidative stress induced by" OR 
"neuropathology induced by" OR "diabetes induced by" OR "hypertension induced by" OR 
"high cholesterol induced by" OR "hypercholesterolemia induced by" OR "obesity induced by" 
OR "metabolic syndrome induced by")  
AND 
MESH HEADING NO EXPLODE 
Lipopolysaccharides OR Malondialdehyde OR Neurotoxicity Syndromes OR Carbon 
Tetrachloride OR Formaldehyde OR 9,10-Dimethyl-1,2-benzanthracene OR 
Trinitrobenzenesulfonic Acid OR Insecticides OR Endocrine Disruptors OR Diethylnitrosamine 
OR Hydrogen Peroxide OR Benzhydryl Compounds OR Chemical Warfare Agents OR Asbestos 
OR Herbicides OR Organometallic Compounds OR Scopolamine Hydrobromide OR Silicon 
Dioxide OR Polychlorinated Biphenyls OR 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine OR 
Benzo(a)pyrene OR Fluorocarbons OR Nitrogen Dioxide OR Polycyclic Hydrocarbons, 
Aromatic OR Tetrachlorodibenzodioxin OR Metals, Heavy OR Hydrocarbons, Chlorinated OR 
Chemical Industry OR 1,2-Dimethylhydrazine OR Ethylene Glycol OR Nitrosamines OR 
Benzene OR Fluorides OR Agricultural Workers' Diseases OR Bromodeoxyuridine OR 
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Chromium OR Organophosphorus Compounds OR Organic Chemicals OR Carbon Monoxide 
OR Benzalkonium Compounds OR Chlorpyrifos OR Organophosphates OR Organophosphate 
Poisoning OR Volatile Organic Compounds OR Diethylhexyl Phthalate OR Sulfur Dioxide OR 
Petroleum OR Methylmercury Compounds OR Chlorine OR Dichlorodiphenyl Dichloroethylene 
OR Hydrocarbons OR Trichloroethylene OR Carbon Tetrachloride Poisoning OR 3,4-
Dihydroxyphenylacetic Acid OR Alkanesulfonic Acids OR Plasticizers OR Halogenated 
Diphenyl Ethers OR Benzene Derivatives OR Dinitrofluorobenzene OR Toluene 2,4-
Diisocyanate OR Benzopyrenes OR Cyclohexenes OR Nitrobenzenes OR Plastics OR 
Trihalomethanes OR Hydrocarbons, Brominated 
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Appendix 9A-2 - Unambiguous MeSH Terms - Streamlined Approach 
("Drug-Related Side Effects AND Adverse Reactions" OR Abnormalities, Drug Induced OR 
Abnormalities, Radiation-Induced OR Agricultural Workers Diseases OR Aids Related 
Opportunistic Infections OR Air Pollutants OR Air Pollutants, Occupational OR Air Pollutants, 
Radioactive OR Air Pollution OR Air Pollution, Indoor OR Air Pollution, Radioactive OR 
Alcohol Drinking OR Alcohol Related Disorders OR Alcoholic Beverages OR Alcoholic 
Intoxication OR Alcoholism OR Amphetamine Related Disorders OR Amphetamines OR 
Arsenic Poisoning OR Asthma, Aspirin-Induced OR Asthma, Exercise-Induced OR Asthma, 
Occupational OR Behavior, Addictive OR Bullying OR Cadmium Poisoning OR Carbon 
Monoxide Poisoning OR Carbon Tetrachloride Poisoning OR Carcinogenicity Tests OR 
Carcinogens OR Carcinogens, Environmental OR Causality OR Cardiomegaly, Exercise-
Induced OR Chemical Warfare Agents OR Chemically-Induced Disorders OR Child Abuse OR 
Child Abuse, Sexual OR Cholesterol, Dietary OR Ciguatera Poisoning OR Cocaine Related 
Disorders OR Cytomegalovirus Infections OR Dermatitis, Occupational OR Diet, Atherogenic 
OR Diet, High Fat OR Dietary Carbohydrates OR Dietary Fats OR Dietary Fats, Unsaturated OR 
Dietary Fiber OR Dietary Sucrose OR Domestic Violence OR Drug Contamination OR Drug 
Eruptions OR Drug Hypersensitivity OR Drug Overdose OR Drug-Induced Liver Injury OR 
Dyskinesia, Drug Induced OR Eating Disorders OR Environmental Exposure OR Environmental 
Illness OR Environmental Pollutants OR Environmental Pollution OR Environmental Pollution 
OR Escherichia Coli Infections OR Fast Foods OR Fluoride Poisoning OR Food Additives OR 
Food Contamination OR Food Hypersensitivity OR Foodborne Diseases OR Gas Poisoning OR 
Hazardous Substances OR Hazardous Waste OR Hearing Loss, Noise Induced OR Heavy Metal 
Poisoning, Nervous System OR Hepatitis A, Chronic OR Hepatitis B, Chronic OR Hepatitis C, 
Chronic OR Heroin Dependence OR Herpesviridae Infections OR Htlv I Infections OR 
Hypersensitivity OR Hypersensitivity, Delayed OR Hypersensitivity, Immediate OR Iatrogenic 
Disease OR Inhalation Exposure OR Iron Overload OR Lead Poisoning OR Lead Poisoning, 
Nervous System OR Lead Poisoning, Nervous System, Adult OR Lead Poisoning, Nervous 
System, Childhood OR Leukemia, Radiation Induced OR Manganese Poisoning OR Marijuana 
Abuse OR Maternal Exposure OR Mercury Poisoning OR Mercury Poisoning, Nervous System 
OR Morphine Dependence OR Mptp Poisoning OR Mushroom Poisoning OR Mutagenicity 
Tests OR Mutagens OR Neoplasms, Radiation Induced OR Neurotoxicity Syndromes OR 
Occupational Diseases OR Occupational Exposure OR Opioid Related Disorders OR 
Opportunistic Infections OR Organophosphate Poisoning OR Paternal Exposure OR Plant 
Poisoning OR Pneumonia, Ventilator-Associated OR Poisoning OR Poisons OR Prenatal 
Exposure Delayed Effects OR Psychoses, Substance Induced OR Radiation Effects OR 
Radiation Injuries OR Radioactive Hazard Release OR Radioactive Pollutants OR Respiratory 
Hypersensitivity OR Salmonella Food Poisoning OR Sedentary Lifestyle OR Shellfish Poisoning 
OR Sleep Deprivation OR Sleep Disorders OR Sodium Chloride, Dietary OR Sodium, Dietary 
OR Soil Pollutants OR Soil Pollutants, Radioactive OR Spouse Abuse OR Staphylococcal Food 
Poisoning OR Staphylococcal Infections OR Streptococcal Infections OR Substance Abuse, 
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Intravenous OR Substance Withdrawal Syndrome OR Substance-Related Disorders OR 
Teratogens OR Tobacco Smoke Pollution OR Tobacco Use Disorder OR Toxicity Tests, Chronic 
OR Virus Diseases OR Vitamin D Deficiency OR Water Pollutants OR Water Pollutants, 
Chemical OR Water Pollutants, Radioactive OR Water Pollution OR Water Pollution, Chemical)  
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